Latest Projects and Scientific Studies
Actively Recruiting
ESCAPE NA-1
To determine the efficacy of the neuro protctant NA-1 in reducing global disability in subjects with AIS with a small established infarct core and good collateral circulation selected for EVT.
The study is currently actively recruiting at multiple international sites!
New Study
UNMASK EVT
An international multidisciplinary survey to examine decisions in EVT care across the world. What factors govern the selection for EVT in the real-world.
In Progress
TEMPO 2 Study
To demonstrate the efficacy of using TNK-tPA to treat minor ischemic stroke in proven arterial occlusion.
A Phase 3, prospective, randomized controlled, open-‐label with blinded outcome assessment (PROBE) controlled trial.
IDEF (NIH-NINDS)
The focus of this study is to evaluate the investigational drug, deferoxamine mesylate or deferoxamine. This drug removes iron. Blood in the brain after a brain hemorrhage contains iron and this iron damages the brain. We are studying whether removal of iron from the brain hemorrhage will reduce the effects of the brain hemorrhage. We will look specifically at a person’s ability to function well and to think well after a brain hemorrhage. We will also learn more about the safety of the investigational drug.
DATAS II
Establish the safety of early anticoagulation with the novel oral anticoagulant dabigatran in acute cerebrovascular syndrome patients.
Identify the rate of both symptomatic and asymptomatic hemorrhagic transformation (HT) associated with these treatments.
Identify predictors of HT associated with acute dabigatran treatment.
Hypothesis: The Investigators hypothesize that symptomatic HT rates in dabigatran and ASA treated patients will not be significantly different.
